Occurrence of tinnitus and peripheral sensory neuropathy in women during chemotherapy treatment of breast cancer
Revista Ciências em Saúde
Occurrence of tinnitus and peripheral sensory neuropathy in women during chemotherapy treatment of breast cancer
Autor Correspondente: Barbosa-Lima R | [email protected]
Palavras-chave: breast neoplasms, drug-related side effects and adverse reactions, drug therapy, ototoxicity, tinnitus
Resumos Cadastrados
Resumo Português:
Objetivo: Analisar a ocorrência de zumbido e neuropatia sensorial periférica em mulheres durante quimioterapia para câncer de mama. Métodos: Trata-se de um estudo analítico e retrospectivo com abordagem quantitativa, realizado em prontuários de um serviço ambulatorial de oncologia entre fevereiro de 2014 e fevereiro de 2015, utilizando os escores de toxicidades do Common Terminology Criteria for Adverse Events (CTCAE). Resultados: Das 181 pacientes com câncer de mama que atenderam aos critérios de inclusão, 49.2% relataram zumbido e 65.1% neuropatia sensorial periférica em algum momento do tratamento. Em ambas as condições, o escore de gravidade predominante foi grau 1, com frequências de 23.8% e 33.1%, respectivamente. Foi observada uma correlação significativa, positiva e fraca entre a severidade do zumbido e da neuropatia sensorial periférica (ρ = 0,325 e p = 0,001), bem como muito fraca entre a quantidade de ciclos completos de quimioterapia e zumbido (ρ = 0,195 e p = 0,009) e neuropatia sensorial periférica (ρ = 0,237 e p = 0,002). Conclusões: Zumbido e neuropatia sensorial periférica foram toxicidades frequentes durante o tratamento quimioterápico do câncer de mama e ambos se manifestaram com baixa gravidade/impacto funcional na maioria das participantes.
Resumo Inglês:
Objective: To analyze the occurrence of tinnitus and peripheral sensory neuropathy in women during breast cancer chemotherapy. Methods: This is a retrospective analytical study with a quantitative approach, performed in medical records of an oncology outpatient service between February 2014 and February 2015, using the toxicities scores of Common Terminology Criteria for Adverse Events (CTCAE). Results: Considering 181 patients with breast cancer who met the inclusion criteria, 49.2% reported tinnitus at some point of the treatment, while 65.1% peripheral sensory neuropathy. In both conditions, the predominant severity score was grade 1, with frequencies of 23.8% and 33.1%, respectively. A significant, positive and weak correlation was observed between the severity of tinnitus and peripheral sensory neuropathy (ρ = 0.325 and p = 0.001), as well as very weak between the number of complete cycles of chemotherapy and tinnitus (ρ = 0.195 and p = 0.009) and neuropathy peripheral sensory (ρ = 0.237 and p = 0.002). Conclusions: Tinnitus and peripheral sensory neuropathy were frequent toxicities during chemotherapy treatment of breast cancer, and both manifested with low severity/functional impact in most participants.